Reference Interval:
By report
|
| Interpretive Data: |
Test Information: HIV-1 Genotype
This assay predicts HIV-1 resistance to protease and reverse transcriptase inhibitor anti-retroviral drugs. The entire protease gene and codons 1-335 of the reverse transcriptase gene of the viral genome are sequenced at ARUP Laboratories using the Viroseq™ HIV-1 Genotyping System kit. Viroseq™ HIV-1 Genotyping software assigns drug resistance based on the sample sequence. For the most current resistance algorithm and drug list, see the Drugs and Mutations link above.
A patient's response to therapy depends on multiple factors including the percentage of a patient's viral population that is resistant, patient compliance, access to adequate care, optimal dosing, and drug pharmacology issues, including absorption, elimination, and drug interactions. Therefore, this test should be used only in conjunction with clinical presentation and other laboratory markers (e.g., symptoms, treatment history, clinical impressions, results from other tests, etc.) when making therapeutic decisions. Results from different test methods/algorithms may provide different resistance interpretation.
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma, as measured with the Roche Amplicor HIV-1 Monitor assay (Roche Diagnostic Systems, Branchburg, NJ). This test does not detect minor HIV-1 populations that are less than approximately 20 percent of the total population.
The ARUP HIV-1 Genotyping Assay uses the Viroseq™ HIV-1 Genotyping System Software to identify mutations associated with drug resistance. According to the Viroseq™ software manual, some insertions/deletions may be difficult to detect using this software; therefore, in rare cases, insertions/deletions in the viral sequence may result in an inaccurate drug resistance report.
The performance characteristics of this test were determined by ARUP Laboratories, Inc.
|
| Note: |
HIV-1 genotyping analysis is now available for the following anti-retroviral drugs:
Nucleoside Reverse Transcriptase InhibitorsProtease Inhibitors
Generic Name Trade Name Code Generic Name Trade Name Code
Zidovudine Retrovir® AZT, ZDV Saquinavir Fortovase® SQV
Didanosine Videx® DDI Ritonovir Norvir® RTV
Tipranavir Aptivus Indinavir Crixivan® IDV
Lamivudine Epivir® 3TC Nelfinavir Viracept® NFV
Stavudine Zerit® D4T Lopinavir/Ritonavir Kaletra® LPV
Abacavir Ziagen® ABC Amprenavir Agenerase® APV
Tenofovir Viread® TDF *Fosamprenavir Lexiva® FOS
*Emtricitabine Emtriva® FTC *Atazanavir Reyataz® ATV
Non-Nucleoside Reverse Transcriptase Inhibitors
Generic Name Trade Name Code
Nevirapine Viramune® NVP
Delavirdine Rescriptor® DLV
Efavirenz Sustiva® EFV
*These drugs have been added as of September 13, 2004.
|
| CPT Code(s): |
87901
|
|
![[ image for: Drugs and Mutation List]](icon_40.jpg){kind=icon}